| Elizabeth Elaine Bebout, LPN | |
|
721 K St, Lincoln, NE 68508-2949 | |
| (402) 477-3951 | |
| (402) 477-9117 |
| Full Name | Elizabeth Elaine Bebout |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 721 K St, Lincoln, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003106808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 20782 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Elaine Bebout, LPN 721 K St, Lincoln, NE 68508-2949 Ph: (402) 477-3951 | Elizabeth Elaine Bebout, LPN 721 K St, Lincoln, NE 68508-2949 Ph: (402) 477-3951 |
News Archive
Oceans Omega, a leading supplier of water-soluble omega-3 EPA and DHA ingredients for food, beverage, nutritional and pet care products, announced today the world's first commercially produced omega-3 fortified gelatins.
The results of a meta-analysis of individual patient data show that vitamin D supplementation with calcium reduces mortality rates in the elderly.
Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.
The use of androgen deprivation therapies to prevent precancerous prostate abnormalities developing into aggressive prostate cancer may have adverse effects in men with precancers with specific genetic alterations, according to data from a preclinical study recently published in Cancer Discovery, a journal of the American Association for Cancer Research.
Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.
› Verified 6 days ago
Lavonne Jean Hohenfeldt, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 5021 Orchard St, Lincoln, NE 68504 Phone: 402-436-1164 Fax: 402-458-3264 | |
Linda Janette Deboer, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 5905 O St, Lincoln, NE 68510 Phone: 402-436-1000 | |
Ms. Tara Johnson, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: Lpsdo 5905 O St, Lincoln, NE 68510 Phone: 402-436-1657 | |
Mrs. Kathy Hottovy, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 5905 O St, Lincoln, NE 68510 Phone: 402-436-1000 Fax: 402-436-1686 | |
Kyla Dickinson, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6900 Adams St, Lincoln, NE 68507 Phone: 830-377-8843 | |
Sara Bennett, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 5905 O St, Lincoln, NE 68510 Phone: 402-436-1000 |